Stocktoria
Sanofi SAN.PA
FR · Euronext Paris · XPAR · stock · Healthcare · website
Sanofi financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | €46.7B | €44.3B | €41.6B | €40.6B |
| Gross profit | €33.7B | €31.1B | €29.0B | €28.7B |
| R&D expense | €7.8B | €7.4B | €6.5B | €6.5B |
| SG&A expense | €10.2B | €9.8B | €9.5B | €8.7B |
| Operating income | €9.6B | €8.9B | €8.7B | €10.9B |
| Interest expense | €626.0M | €704.0M | €643.0M | €465.0M |
| Income tax | €1.0B | €1.2B | €1.0B | €1.9B |
| Net income | €7.8B | €5.6B | €5.4B | €8.4B |
| EPS (diluted) | €6.40 | €4.59 | €4.31 | €5.37 |
| Operating cash flow | €10.8B | €9.1B | €10.3B | €10.5B |
| Free cash flow | €7.2B | €5.9B | €7.4B | €8.4B |
| Cash & equivalents | €7.7B | €7.4B | €8.7B | €12.7B |
| Inventory | €10.2B | €9.4B | €9.7B | €9.0B |
| Goodwill | €41.3B | €43.4B | €49.4B | €49.9B |
| Total assets | €126.8B | €132.8B | €126.5B | €126.7B |
| Total debt | €20.3B | €17.9B | €18.4B | €21.2B |
| Total liabilities | €55.1B | €54.9B | €52.1B | €51.6B |
| Shareholders' equity | €71.4B | €77.5B | €74.0B | €74.8B |
| Share buybacks | €5.0B | €302.0M | €593.0M | €497.0M |
Growth · year-over-year · Revenue CAGR 4.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue growth | +5.5% | +6.4% | +2.6% | — |
| Net income growth | +40.5% | +3.0% | -35.5% | — |
| EPS growth | +39.4% | +6.5% | -19.7% | — |
| Free cash flow growth | +22.5% | -19.9% | -12.7% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · FR · as of 2025-12-31. Figures in EUR. Facts plus Stocktoria's own computed scores — not investment advice.